Skip to Content
Merck
  • Histamine in the locus coeruleus promotes descending noradrenergic inhibition of neuropathic hypersensitivity.

Histamine in the locus coeruleus promotes descending noradrenergic inhibition of neuropathic hypersensitivity.

Pharmacological research (2014-10-12)
Hong Wei, Cong-Yu Jin, Hanna Viisanen, Hao-Jun You, Antti Pertovaara
ABSTRACT

Among brain structures receiving efferent projections from the histaminergic tuberomammillary nucleus is the pontine locus coeruleus (LC) involved in descending noradrenergic control of pain. Here we studied whether histamine in the LC is involved in descending regulation of neuropathic hypersensitivity. Peripheral neuropathy was induced by unilateral spinal nerve ligation in the rat with a chronic intracerebral and intrathecal catheter for drug administrations. Mechanical hypersensitivity in the injured limb was assessed by monofilaments. Heat nociception was assessed by determining radiant heat-induced paw flick. Histamine in the LC produced a dose-related (1-10μg) mechanical antihypersensitivity effect (maximum effect at 15min and duration of effect 30min), without influence on heat nociception. Pretreatment of LC with zolantidine (histamine H2 receptor antagonist), but not with pyrilamine (histamine H1 receptor antagonist), and spinal administration of atipamezole (an α2-adrenoceptor antagonist), prazosine (an α1-adrenoceptor antagonist) or bicuculline (a GABAA receptor antagonist) attenuated the antihypersensitivity effect of histamine. The histamine-induced antihypersensitivity effect was also reduced by pretreatment of LC with fadolmidine, an α2-adrenoceptor agonist inducing autoinhibition of noradrenergic cell bodies. Zolantidine or pyrilamine alone in the LC failed to influence pain behavior, while A-960656 (histamine H3 receptor antagonist) suppressed hypersensitivity. A plausible explanation for these findings is that histamine, due to excitatory action mediated by the histamine H2 receptor on noradrenergic cell bodies, promotes descending spinal α1/2-adrenoceptor-mediated inhibition of neuropathic hypersensitivity. Blocking the autoinhibitory histamine H3 receptor on histaminergic nerve terminals in the LC facilitates release of histamine and thereby, increases descending noradrenergic pain inhibition.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Lidocaine, powder
Sigma-Aldrich
Histamine, ≥97.0%
Sigma-Aldrich
Lidocaine, analytical standard
Sigma-Aldrich
Cimetidine
USP
Lidocaine, United States Pharmacopeia (USP) Reference Standard
Lidocaine, European Pharmacopoeia (EP) Reference Standard
Supelco
Lidocaine, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Cimetidine, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Histamine, analytical standard
USP
Cimetidine, United States Pharmacopeia (USP) Reference Standard
Lysine hydrochloride, European Pharmacopoeia (EP) Reference Standard
Cimetidine, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Pyrilamine maleate salt
Sigma-Aldrich
Histamine dihydrochloride, ≥99% (TLC), powder
Sigma-Aldrich
L-Lysine monohydrochloride, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, 98.5-101.0%
Sigma-Aldrich
Histamine dihydrochloride, ≥99.0% (AT)
Sigma-Aldrich
L-Lysine monohydrochloride, BioUltra, ≥99.5% (AT)
Sigma-Aldrich
(+)-Bicuculline, ≥97.0% (TLC)
Supelco
L-Lysine hydrochloride solution, 100 mM amino acid in 0.1 M HCl, analytical standard
Sigma-Aldrich
L-Lysine monohydrochloride, reagent grade, ≥98% (HPLC)
Supelco
Pyrilamine maleate, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
L-Lysine monohydrochloride, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Supelco
L-Lysine monohydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
Mepyramine maleate, European Pharmacopoeia (EP) Reference Standard
Histamine dihydrochloride, European Pharmacopoeia (EP) Reference Standard